company background image
DXCM logo

DexCom NasdaqGS:DXCM 株式レポート

最終価格

US$75.24

時価総額

US$29.2b

7D

3.7%

1Y

-32.1%

更新

20 Nov, 2024

データ

会社財務 +

DexCom, Inc.

NasdaqGS:DXCM 株式レポート

時価総額:US$29.2b

DXCM 株式概要

医療機器メーカーであるDexCom, Inc.は、継続的グルコースモニタリング(CGM)システムの設計、開発、商品化に注力し、米国および国際的に展開している。 詳細

DXCM ファンダメンタル分析
スノーフレーク・スコア
評価4/6
将来の成長4/6
過去の実績5/6
財務の健全性6/6
配当金0/6

Community Narratives

Create a narrative

Narratives bring a range of perspectives from our community.

DexCom, Inc. 競合他社

価格と性能

の歴代最高値、変動、値下がりまとめDexCom
過去の株価
現在の株価US$75.24
52週高値US$142.00
52週安値US$62.34
ベータ1.17
11ヶ月の変化3.62%
3ヶ月変化4.10%
1年変化-32.09%
33年間の変化-49.72%
5年間の変化32.27%
IPOからの変化2,463.54%

最新ニュース

Recent updates

Are Investors Undervaluing DexCom, Inc. (NASDAQ:DXCM) By 44%?

Nov 08
Are Investors Undervaluing DexCom, Inc. (NASDAQ:DXCM) By 44%?

DexCom Growing Into Its Valuation, But Still No Bargain

Oct 25

DexCom, Inc.'s (NASDAQ:DXCM) Price In Tune With Earnings

Oct 21
DexCom, Inc.'s (NASDAQ:DXCM) Price In Tune With Earnings

DexCom Q3 Preview: Walking On Eggshells With Its Channel Relationships

Oct 16

These 4 Measures Indicate That DexCom (NASDAQ:DXCM) Is Using Debt Safely

Sep 30
These 4 Measures Indicate That DexCom (NASDAQ:DXCM) Is Using Debt Safely

DexCom: Investors Discounting Long CGM Growth Runway

Sep 19

We Like These Underlying Return On Capital Trends At DexCom (NASDAQ:DXCM)

Sep 16
We Like These Underlying Return On Capital Trends At DexCom (NASDAQ:DXCM)

DexCom Q2 Earnings: Traditional Market Overreaction

Aug 07

Is Now The Time To Look At Buying DexCom, Inc. (NASDAQ:DXCM)?

Jul 26
Is Now The Time To Look At Buying DexCom, Inc. (NASDAQ:DXCM)?

DexCom Q2: Surprising Earnings Miss With Hints Of Competitive Pressures

Jul 26

Why Investors Shouldn't Be Surprised By DexCom, Inc.'s (NASDAQ:DXCM) P/E

Jul 12
Why Investors Shouldn't Be Surprised By DexCom, Inc.'s (NASDAQ:DXCM) P/E

DexCom's ADA Conference Takeaways: Stelo, CGM Tailwinds Still Intact

Jul 03

DexCom (NASDAQ:DXCM) Seems To Use Debt Rather Sparingly

Jun 28
DexCom (NASDAQ:DXCM) Seems To Use Debt Rather Sparingly

Calculating The Fair Value Of DexCom, Inc. (NASDAQ:DXCM)

Jun 03
Calculating The Fair Value Of DexCom, Inc. (NASDAQ:DXCM)

Dexcom: Positive Catalysts Ahead To Support Growth

May 13

If EPS Growth Is Important To You, DexCom (NASDAQ:DXCM) Presents An Opportunity

May 07
If EPS Growth Is Important To You, DexCom (NASDAQ:DXCM) Presents An Opportunity

DexCom: Attractive Discount After Strong Earnings Results

May 06

Returns At DexCom (NASDAQ:DXCM) Are On The Way Up

Apr 25
Returns At DexCom (NASDAQ:DXCM) Are On The Way Up

Why We're Not Concerned About DexCom, Inc.'s (NASDAQ:DXCM) Share Price

Apr 12
Why We're Not Concerned About DexCom, Inc.'s (NASDAQ:DXCM) Share Price

DexCom Is Pricey For A Reason - Its Growth Story Reflects That

Apr 11

Is DexCom (NASDAQ:DXCM) Using Too Much Debt?

Mar 29
Is DexCom (NASDAQ:DXCM) Using Too Much Debt?

Should You Think About Buying DexCom, Inc. (NASDAQ:DXCM) Now?

Mar 04
Should You Think About Buying DexCom, Inc. (NASDAQ:DXCM) Now?

DexCom: A Wealth Compounder In Healthcare

Feb 14

DexCom: Stelo Stellar Outlook

Jan 17

DexCom (NASDAQ:DXCM) Is Experiencing Growth In Returns On Capital

Jan 15
DexCom (NASDAQ:DXCM) Is Experiencing Growth In Returns On Capital

DexCom, Inc. (NASDAQ:DXCM) Not Lagging Industry On Growth Or Pricing

Jan 01
DexCom, Inc. (NASDAQ:DXCM) Not Lagging Industry On Growth Or Pricing

DexCom (NASDAQ:DXCM) Seems To Use Debt Rather Sparingly

Dec 18
DexCom (NASDAQ:DXCM) Seems To Use Debt Rather Sparingly

A Look At The Fair Value Of DexCom, Inc. (NASDAQ:DXCM)

Dec 05
A Look At The Fair Value Of DexCom, Inc. (NASDAQ:DXCM)

At US$109, Is It Time To Put DexCom, Inc. (NASDAQ:DXCM) On Your Watch List?

Nov 21
At US$109, Is It Time To Put DexCom, Inc. (NASDAQ:DXCM) On Your Watch List?

DexCom (NASDAQ:DXCM) Is Looking To Continue Growing Its Returns On Capital

Sep 28
DexCom (NASDAQ:DXCM) Is Looking To Continue Growing Its Returns On Capital

DexCom (NASDAQ:DXCM) Could Easily Take On More Debt

Sep 13
DexCom (NASDAQ:DXCM) Could Easily Take On More Debt

Calculating The Fair Value Of DexCom, Inc. (NASDAQ:DXCM)

Aug 29
Calculating The Fair Value Of DexCom, Inc. (NASDAQ:DXCM)

Should You Think About Buying DexCom, Inc. (NASDAQ:DXCM) Now?

Aug 14
Should You Think About Buying DexCom, Inc. (NASDAQ:DXCM) Now?

DexCom (NASDAQ:DXCM) Has A Rock Solid Balance Sheet

Jun 05
DexCom (NASDAQ:DXCM) Has A Rock Solid Balance Sheet

There's Been No Shortage Of Growth Recently For DexCom's (NASDAQ:DXCM) Returns On Capital

May 16
There's Been No Shortage Of Growth Recently For DexCom's (NASDAQ:DXCM) Returns On Capital

Do DexCom's (NASDAQ:DXCM) Earnings Warrant Your Attention?

Mar 21
Do DexCom's (NASDAQ:DXCM) Earnings Warrant Your Attention?

These 4 Measures Indicate That DexCom (NASDAQ:DXCM) Is Using Debt Safely

Mar 03
These 4 Measures Indicate That DexCom (NASDAQ:DXCM) Is Using Debt Safely

DexCom (NASDAQ:DXCM) Is Doing The Right Things To Multiply Its Share Price

Feb 13
DexCom (NASDAQ:DXCM) Is Doing The Right Things To Multiply Its Share Price

株主還元

DXCMUS Medical EquipmentUS 市場
7D3.7%-0.4%-1.0%
1Y-32.1%20.3%30.3%

業界別リターン: DXCM過去 1 年間で20.3 % の収益を上げたUS Medical Equipment業界を下回りました。

リターン対市場: DXCMは、過去 1 年間で30.3 % のリターンを上げたUS市場を下回りました。

価格変動

Is DXCM's price volatile compared to industry and market?
DXCM volatility
DXCM Average Weekly Movement4.4%
Medical Equipment Industry Average Movement8.2%
Market Average Movement6.2%
10% most volatile stocks in US Market15.7%
10% least volatile stocks in US Market3.1%

安定した株価: DXCM過去 3 か月間に大きな価格変動はありませんでした。

時間の経過による変動: DXCMの 週次ボラティリティ ( 4% ) は過去 1 年間安定しています。

会社概要

設立従業員CEO(最高経営責任者ウェブサイト
19999,550Kevin Sayerwww.dexcom.com

医療機器メーカーであるDexCom, Inc.は、継続的グルコースモニタリング(CGM)システムの設計、開発、商品化に注力し、米国および国際的に展開している。同社は、糖尿病患者や医療従事者が使用するシステムを提供している。同社の製品には、糖尿病管理用の統合型CGMシステムであるDexcom G6およびDexcom G7、遠隔モニタリングシステムであるDexcom Share、認定されたサードパーティのソフトウェア開発者がリアルタイムのCGMデータをデジタルヘルスアプリやデバイスに統合できるようにするDexcom Real-Time API、糖尿病治療の意思決定のための指スティック血糖測定に取って代わるように設計されたDexcom ONEなどがある。また、2型糖尿病患者向けのDexcom SteloのFDA審査を申請している。同社はVerily Life Sciences LLCおよびVerily Ireland Limitedと、血液ベースまたは間質性グルコースモニタリング製品の開発に関する提携およびライセンス契約を結んでいる。同社は製品を内分泌専門医、医師、糖尿病教育者に直接販売している。同社は1999年に設立され、カリフォルニア州サンディエゴに本社を置いている。

DexCom, Inc. 基礎のまとめ

DexCom の収益と売上を時価総額と比較するとどうか。
DXCM 基礎統計学
時価総額US$29.25b
収益(TTM)US$680.80m
売上高(TTM)US$3.95b

43.2x

PER(株価収益率

7.4x

P/Sレシオ

収益と収入

最新の決算報告書(TTM)に基づく主な収益性統計
DXCM 損益計算書(TTM)
収益US$3.95b
売上原価US$1.52b
売上総利益US$2.44b
その他の費用US$1.76b
収益US$680.80m

直近の収益報告

Sep 30, 2024

次回決算日

該当なし

一株当たり利益(EPS)1.74
グロス・マージン61.68%
純利益率17.22%
有利子負債/自己資本比率123.3%

DXCM の長期的なパフォーマンスは?

過去の実績と比較を見る